AU7746091A - Methods of tissue implantation - Google Patents
Methods of tissue implantationInfo
- Publication number
- AU7746091A AU7746091A AU77460/91A AU7746091A AU7746091A AU 7746091 A AU7746091 A AU 7746091A AU 77460/91 A AU77460/91 A AU 77460/91A AU 7746091 A AU7746091 A AU 7746091A AU 7746091 A AU7746091 A AU 7746091A
- Authority
- AU
- Australia
- Prior art keywords
- tissue
- cam
- mammalian
- implantation
- egg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 66
- 238000002513 implantation Methods 0.000 title claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 107
- 210000003711 chorioallantoic membrane Anatomy 0.000 claims description 69
- 239000007943 implant Substances 0.000 claims description 36
- 210000000981 epithelium Anatomy 0.000 claims description 25
- 210000001161 mammalian embryo Anatomy 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 19
- 230000001143 conditioned effect Effects 0.000 claims description 18
- 230000004720 fertilization Effects 0.000 claims description 17
- 210000000287 oocyte Anatomy 0.000 claims description 14
- 241001455272 Amniota Species 0.000 claims description 13
- 201000004384 Alopecia Diseases 0.000 claims description 12
- 241000271566 Aves Species 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
- 206010034010 Parkinsonism Diseases 0.000 claims description 9
- 210000002459 blastocyst Anatomy 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 6
- 210000001577 neostriatum Anatomy 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 230000002500 effect on skin Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 230000003779 hair growth Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229920003023 plastic Polymers 0.000 claims description 5
- 210000003754 fetus Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 241000287826 Gallus Species 0.000 claims description 3
- 241000272533 Struthio Species 0.000 claims description 3
- 210000001943 adrenal medulla Anatomy 0.000 claims description 3
- 210000003780 hair follicle Anatomy 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 2
- 102000001974 Hyaluronidases Human genes 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 229960002773 hyaluronidase Drugs 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 230000004077 genetic alteration Effects 0.000 claims 1
- 231100000118 genetic alteration Toxicity 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 description 43
- 238000011282 treatment Methods 0.000 description 16
- 210000003161 choroid Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 241000272534 Struthio camelus Species 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001919 adrenal effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000991 chicken egg Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 241000938605 Crocodylia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000036621 balding Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Virology (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
METHODS OF TISSUE IMPLANTATION
Technical Field
This invention relates generally to methods of implanting and reimplanting mammalian tissue in mammals. More specifically, the invention relates to: procedures which increase implantation efficiency; methods of treatment which involve implantation; and tissue compositions useful for implantation.
Description of Related Art
The chorioallantoic membrane (CAM) is a heavily vascularized, extraembryonic, fetal membrane of birds. It provides essential gas exchange for the developing avian embryo. Due to its easy access and proximal separation from the embryo it has been studied and utilized by both developmental and tumor biologists.
Beginning in the early part of this century, the CAM was commonly used to study the growth of small tumor transplants (Karnofsky et al, Ann NY Acad Sci (1952) 5_5:313. More recently, it has been used in studies of membrane transport, gas exchange, and angiogenic activity. The CAM has also been used in developmental studies as a substrate for the growth of many types of embryonic avian tissues and organ primordia (Rawles, Ann NY Acad Sci (1952) 55:302) . Ebert cultured organ explants from post-hatch chickens on CAM tissue to study the effects of the explants on the corresponding tissues in the developing egg (Proc Nat Acad (1954) .40:337; J Nat Cancer Inst (1960)
2.:73). Hurst et al has reported that some normal human tissue grown on the CAM showed mitotic activity (Austr J EXP Biol (1939) 12:215), however contrary reports have indicated that adult endothelial tissue does not survive more than three days when implanted on the CAM (Ausprunk & Folkman, Virchows Arch B Cell Path (1976) 21:31) . Implantation as a method of treatment has found many applications in medicine. However, the widespread use of implantation has always been limited by the efficiency of survival of the implanted tissue. For example hair transplantation is used to treat alopecia (hair-loss) . Scalp baldness may be treated by surgical transplantation of active hair follicles to the scalp.
Recent reports have suggested that the symptoms of Parkinsonism can be ameliorated by autogenic implantation of adrenal medullary tissue to the striatum of the brain, but the transplanted tissue survives for only a relatively short time (Ding, Y.J. et al, Chin Med J. (1988) 101:631; Hansen, J.T. et al, Exp Neurol (1988) 102:65; Stromberg, I. et al, Exp Brain Res(1985) 60:335) . Most recently, Brundin et al (Exp Brain Res(1988) 70:192) has reported that human fetal dopamine neurons can be similarly used in rats; and Lindvall et al (Arch Neurol (1989) 46:615) has reported some success in humans. Implantation is an important step in the early development of mammalian embryos. Techniques of in vitro fertilization are being more widely applied, employing both immediate and cryogenically delayed implantation (Camus, M. et al, Fert and Steril (1989) 51:460), but again implantation efficiency has proven to be a limitation (Liu, H.C. et al, Fert and Steril
(1988) 49:649). iemer et al (Fert and Steril (1989) 52:503) has reported that implantation efficiency increases if human zygotes are co-cultured on a monolayer of fetal bovine uterine fibroblasts.
Finally, gene therapy has been proposed as a method of treatment for various metabolic deficiencies as well as illness which require the chronic administration of ameliorative proteins (Green, H. et al, Proc Nat Acad Sci (1979) 76:5665; Palmer et al, Proc Nat Acad Sci (1987) 84:1055), but again the successful reimplantation of genetically engineered tissues presents a limitation of the technique.
Summary of the Invention
One embodiment of the invention is a method of treating a mammal in need of tissue implantation which comprises: providing a developing amniote egg that has a chorioallantoic membrane (CAM) ; implanting mammalian cells or tissue on or in the CAM so as to produce a conditioned mammalian tissue comprising a population of cells; removing the conditioned tissue from the CAM by a means for excision; and, implanting the conditioned tissue in the mammal.
In another embodiment developing chicken eggs of the genus Gallus are used; in yet another embodiment developing ostrich eggs of the genus Struthio are used. In another embodiment, the invention is used to treat both genetic and metabolic deficiencies of gene expression. In still another embodiment, the invention is used to treat alopecia. In other embodiments, the invention is used to treat Parkinsonism.
In yet another embodiment, the invention is sed to facilitate the implantation of mammalian preimplantation embryos into the uterine epithelium of recipient mothers. In another embodiment, the invention provides a method of in vitro fertilization of mammalian oocytes. In a final embodiment, the invention is a composition of tissues useful for mammalian implantations which composition comprises mammalian tissue and growth factors derived from an avian CAM.
Detailed Description of the Invention
Definitions
An "allogeneic" implant comprises cells or tissue which have a different genetic constitution than the host tissue; this because they are obtained from a subject other than the recipient. An "autogenic" implant comprises cells or tissue originating within the body of the recipient (with the same genetic constitution) . Finally, a "homotypic" implant comprises cells or tissue of the same genetic constitution and the same type and function.
"Amplified" tissue is substantially increased in mass as a result of mitotic growth.
An "amniote egg" has a shell and retains its own water supply when external to the parent. It contains a yolk and abundant albumin. The embryo develops within the egg, but external to the parent. Examples include avian and reptile eggs.
"Conditioned tissue" has been grown on the CAM and, as a result, is amplified and substantially vascularized.
A "developing" egg is a fertilized amniote egg which has begun ontogenesis in response to the appropriate conditions of incubation.
A "fertilization unit" is comprised of a mammalian embryo, usually at the blastocyst stage of development, and mammalian uterine epithelial tissue into which the embryo has been implanted. Prior to the implantation of the embryo, the uterine epithelial tissue has been implanted beneath the choroid epithelium of the CAM of a developing amniote egg such as a chicken or ostrich egg. The fertilization unit is subsequently reimplanted in vivo into the uterine epithelium of the mammalian mother.
"Implantation" is the moving of tissue from one site to another and embedding the moved tissue such that it remains viable. Tissue can be implanted at a new site in the original subject or in a heterologous recipient. The implanted tissue can be placed within tissue of similar function or of different function.
A subject which is "in need of" a medical or surgical procedure is one who has an injury, disease, deficiency or medical condition that would likely be ameliorated by the procedure; or alternatively, a subject whose normal physiologic process (e.g. embryo implantation during pregnancy) would be facilitated by the procedure or function. A "neurological impairment" is an injury, disease or degeneration of nerve cells or nervous tissue resulting in a loss of nerve function.
A DNA "structural sequence" encodes a polypeptide. "Transplantation" is a form of implantation in which the tissue being moved is united with the
same tissue-type in another place. If the transplant is from one part of the body to another part it is an "autotransplantation" which is equivalent to a homotypic implant.
"Vascularized" tissue has developed new blbod vessels which are patent to the circulation of the host.
Modes of Carrying Out the Invention
Several injuries, diseases and deficiencies are treatable by tissue implantation and transplantation. In addition, some normal physiologic processes such as mammalian pregnancy involve tissue implantation. The effectiveness of these treatments and the success of these processes is directly related to the efficiency of implantation of the newly introduced tissue as measured by the sustained growth and differentiated function of the implanted tissue.
Disclosed herein are methods of conditioning tissue to increase the efficiency of implantation; treating a mammal in need of implantation with the conditioned tissue; and compositions of tissues useful for such treatment.
Briefly, the methods of conditioning tissue, and its subsequent use in treatment, involve providing an amniote egg with an embryo that has developed a chorioallantoic membrane (CAM) , and implanting mammalian cells or tissue, which are intended to be subsequently implanted in the recipient mammal, onto or into the CAM. The tissue grows and is amplified on or in the CAM as the embryo continues to develop, because patency is established between the circulatory system of the egg and the vasculature of the implant; and because the embryonic environment is rich in
nutrient and growth factors. In addition, the implant tissue becomes hyper-vascularized in response to embryo angiogenic factors. The conditioned mammalian tissue is subsequently excised, along with adherent portions of the CAM, and implanted in a location in the mammalian host which is best suited to the particular treatment regime. The efficiency of implantation is greatly improved, relative to direct tissue implantation, due to the hypervascularization of the implanted tissue, and the tendency of the adherent embryonic vessels to rapidly form functional connections with capillaries of the host tissue. Furthermore, growth factors, provided by the embryonic tissue, may also accompany the implant and promote its integration into the transplantation site.
While this procedure can utilize any amniote egg, in a preferred embodiment, an egg of the class Reptilia or Aves is used. In a more preferred embodiment, eggs of the genus Gallus (chicken) are used. Fertile chicken eggs which have been examined and certified free of pathogens are readily available from commercial sources. Methods of artificial incubation are known to those skilled in the art. In another preferred embodiment, eggs of the genus Struthio (ostrich) are used. While eggs certified pathogen-free are not presently available commercially, ostriches and eggs are commercially available (Big Sky Ostrich Ranch, Plentywood, Montana) and the eggs can be monitored to meet the same standards that are presently used for chick eggs. These methods are generally known to those skilled in the art. Methods of artificial incubation of ostrich eggs are also known (Jarvis, M.J.F., Ostrich (1985) 56:42) .
The technology of preparing the chicken egg and the CAM to receive a tissue implant is well known to those skilled in the art (See e.g. Zwilling, E. , Transplant Bull. (1959) 6:115). The same technology can be generally applied to the amniote eggs of other species with appropriate changes for different gestation periods. This technology has been modified to extend the survival of the implant and enable its subsequent reimplantation in a mammalian host. This modified technique is described below.
A fertile chicken egg, which is pathogen free, is obtained and incubated at 37 degrees Celsius in a humidifier chamber (incubator) for 6 to 9 days prior to implantation of mammalian tissue. The age of the chick embryo determines the amount of mammalian tissue to be implanted. A larger amount of implant tissue requires a more vascularized CAM surface and an increased pumping capacity of the chick heart (an older chick embryo) , which in turn provides a more adequate flow of blood.
The air space at one end of the egg is identified by holding the egg above a small, low intensity light source (candling) and a small (one millimeter) hole is made to allow air to enter the air space. The embryo and the extra-embryonic membranes are then identified, and an "x" is placed with a lead pencil over the mid-portion of the air space to mark its location. A 1 centimeter square window is outlined in the shell centered around the "x" by inscribing lines by means of a small triangular file. The grooves so created are progressively deepened to the egg membrane below. The surface of the egg is cleaned by wiping the area around the "x" with a cotton swab containing 80% ethanol solution for a few
seconds and the surface is allowed to dry. The window is then removed by inserting the tip of a pair of sterile watchmaker's forceps under one corner of the square and lifting to expose the underlying egg membrane.
The egg membrane is carefully penetrated with the tip of the sterile watchmaker's forceps to permit air to enter so that the CAM will detach and
"drop". This membrane is then incised with a sterile scalpel and carefully removed by tearing it away from the perimeter of the window to expose the CAM. The surface of the CAM is inspected at low magnification under a dissecting microscope in order to identify the principal vessels that are then traced to a point of convergence where they form the allantoic vascular supply to the embryo. A provisional site is identified near the convergence of the vessels on the CAM surface for the implantation of mammalian tissue, and the choroid epithelium gently abraded with the tip of a sharp glass needle to provide one or more implantation sites. The window is temporarily closed by placing a small piece of Scotch brand tape over the aperture.
An implant of living tissue is secured under sterile conditions from a deeply anesthetized mammal. Small pieces of live tissue are secured (not exceeding 1 millimeter x 3 millimeters x 1 millimeter) by rapid dissection. The tissue is either immediately placed onto the previously identified CAM implantation site or quickly transferred into a cold (4 degrees Celsius) sterile culture solution situated in a Petri dish.
The cold solution favors survival of cells in the tissue by reducing its metabolic requirements and by permitting diffusion of leukotrienes and
proteins induced by injury which would otherwise create a local inflammatory reaction on the CAM. The tissue then undergoes final trimming to remove surrounding connective tissue and reduction to the desired size. This step is critical to insure the rapid fusion of the choroid vessels with microvasculature elements exposed at the surface of the implant. This is discussed further infra.
The egg is then opened by removal of the tape cover, and the previously identified implantation site is positioned under the egg center of the window by gently rotating the egg. The small pieces of tissue to be implanted are removed from the Petri dish by means of sterile forceps placed gently under each piece, and lifted out of the culture medium. Excess culture medium is rapidly blotted by resting the forceps on sterile absorbent paper, and then delivered to the CAM with a minimal residual quantity of fluid remaining on the surface.
The tissue is gently placed on the surface of the CAM implantation site and carefully moved over the previously abraded surface to secure good contact without inducing additional bleeding from the underlying small capillaries of the choroid surface. In the event that an undue quantity of culture media remains at the CAM implant surface, it is removed by "wicking away" the liquid using the tip of a sterile cellulosic sponge (e.g., tissue paper).
A variety of procedures may be employed to improve the "receptivity" of the CAM which would favor rapid fusion of the choroid vessels with microvascular elements exposed at the surface of the implant. In additional to superficial laceration of the CAM
surface in order to decrease the time required for vascular fusion. Critical to survival of the implant is the rapid fusion of vessels which will provide the implant with blood from the circulatory system of the developing embryo. This fusion is executed within a matter of minutes by micro-vascular elements within the egg which identify the exposed micro-vascular elements of the implant. Little is known of the dynamics involved in this recognition process, but it is assumed to depend, in part, on the superficial location of the extra-embryonic coelomic vessels immediately below or with the choroid epithelial.
Furthermore, the abraded choroid epithelial cells may move away from points of contact with the implanted tissue and to thereby expose underlying vascular elements of the choroid. Vascular fusion is sometimes also favored by covering the implant with a small (5 mm x 5 mm) sterile, transparent plastic "chip" (Gel-Bond, FMC Corp.) whose weight and hydrophyllic surface promote contact with the CAM while preventing drying of the implant.
Following implantation the window of the egg is closed with tape and the edges are sealed by means of paraffin wax applied by means of a hot scalpel blade. The eggs are then incubated at 37 degrees Celsius. Implants may be inspected by placing the egg under the stereoscopic microscope, removing the tape window, and rotating it so the implant is visible. Photographs may also be taken at this and prior stages using the stereoscopic microscope. At high magnifi- cation it is possible to determine the viability of the implant by visualizing blood flow in small surface
vessels which develop at the implant - CAM interface within one or two days after implantation. Such vessels continue to increase in size with time, and certain types of tissue (i.e., adrenal medullary tissues) can be distinguished by virtue of its high degree of vascularization.
Re-implantation of the conditioned implants into a mammalian host is effected by anesthetizing the recipient, and, using standard surgical procedures known to those skilled in the art, exposing a portion of the target organ provided with a non-traumatized micro-vascular bed. In the case of the brain, stereotaxic procedures, known to those skilled in the art, are employed by which the tissue can be delivered into the proper location with minimal trauma.
The implants are readied for reimplantation by first cooling them (while still in the egg) in a refrigerator for a few minutes. The shell window is then opened and approximately 1 to 2 cubic centimeters of cold culture media is used to irrigate the implant surface. After 20 to 30 seconds the culture media is aspirated to expose the implant, and the underlying choroid membrane is carefully stripped away.
In a preferred embodiment, the implant is then removed from the remaining allantoic-mesenchyme surface by means of carefully controlled "aspiration" using a large gauge hypodermic needle whose tip has been modified to provide a sharpened, round, non- oblique aperture. Suction for such aspiration is provided by a tightly fitting "plunger" consisting of a second filled needle which can be withdrawn to create a vacuum. The aspirated tissues in the lumen of the larger (outer) needle shaft can then be safely conveyed to the reimplantation site in the mammalian
host where it can be deposited either on the surface or within the prescribed tissue. In an alternate embodiment, the implant is remove by a circumscribed incision followed by a trimming of surrounding tissue. Of course, it is essential to carry out all of the above reimplantation procedures using sterile technique. It should be also mentioned, however, that a peculiar resistance to infection seems to exist for tissue implanted into the egg. This has so far failed to be reported by other investigators. Thus, it is possible to achieve survival of the implant in the egg without the maintenance of absolute sterility. On the other hand, similar resistance to infectious agents is unlikely to occur for tissue reimplanted into a mammalian host. It is therefore essential to use maximal sterile precautions when engaging in the reimplantation procedures. The following examples are intended to illustrate but not limit the invention.
Example 1 In the Treatment of Alopecia Alopecia (hair-loss) can presently be treated by removing skin plugs from a hair-covered skin area of a balding subject and implanting them in the areas of baldness. This approach is limited because a balding subject has an ever-shrinking reservoir of appropriate hair-covered skin.
Dermal papillae contain cells capable of inducing hair growth, and unknown growth factors, arising from cells in dermal papillae, must be continuously provided to sustain hair growth. Baldness arises from a loss of hair due to a prolonged period of inactivity of the stem cells in the papillae
of particular follicles which give rise to the cells required for hair growth and maintenance. The approach disclosed herein involves elaborating stem cells derived from dermal papillae of active hair follicles on or in the CAM of a chicken egg. Growth of these stem cells on the CAM creates a reservoir of highly active autogenic stem cells and provide a substantial mass of tissue, that is transplantable to areas of baldness.
This autotransplanted tissue is implanted under inactive follicles and subsequently exerts a stimulatory effect on the endogenous stem cells of the dermal papillae, and on related keratinocytes, resulting in hair growth.
Example 2 In the Treatment of Human Infertility The techniques commonly referred to as in vitro fertilization include the collection of oocytes from a donor (which may also be the recipient) the fertilization in vitro of at least one oocyte, and its subsequent reimplantation on or in the uterine epithelium of the recipient mother. One of the most difficult hurdles in this procedure is the reimplantation step. Only one in six (or more) attempts results in a fetus that goes to term.
To improve the efficiency of reimplantation, the fertilized egg is first allowed to implant into uterine epithelial implant tissue (taken from the recipient mother) which is in the process of growing on the CAM. After implantation and establishment of the embryo in this epithelial implant, the entire fertilization unit is then reimplanted into the mother.
Briefly, a small explant of uterine epithelium is obtained either before or at the time of egg recovery and is grown "stroma-down" on the CAM.
While growing on the CAM the uterine epithelium can be prepared to receive the fertilized blastocyst by hormonal conditioning. After fertilization in vitro. the mammalian embryo is transferred to the surface of the uterine tissue explant and allowed to implant. The implantation can be certified by visual inspection. When growth and implantation is assured, the entire fertilization unit, including its highly vascular stroma would be microsurgically reimplanted back into the uterine wall of the mother.
The efficiency of embryo implantation is increased due to the ability to condition the epithelium without exposing the recipient to systemic hormonal treatment, an additional advantage results from the fact that the success of implantation can be ascertained prior to insertion of the embryo into the recipient, thereby avoiding unnecessary patient trauma.
Example 3
In the Treatment of Human Infertility In an alternate embodiment the zygote (fertilized oocyte) is cultured in a small plastic enclosure within the extraembryonic coelom of the CAM rather than first culturing uterine epithelial tissue on the CAM and subsequently implanting the blastocyst into this cultured tissue. The advantage of this approach is that it keeps the entire fertilization unit small (<3mm) which improves the ultimate in vivo reimplantation efficiency.
Example 4 In the Treatment of Human Infertility In an alternate embodiment the oocyte is fertilized directly on the CAM rather than in a culture dish or test tube. A 2mm hole covered with a 3mm gold screen is situated in a sterilized, transparent, hydrophyllic plastic chip (Gel Bond, FMC Corp.) about 3-7mm in diameter. The choroid epithelium is then removed from a 2mm x 2mm site by gentle abrasion with a recently fine-polished glass rod without producing bleeding. The plastic chip containing the gold-covered hole is then placed over the abrasion site on the CAM and the hole allowed to fill with the coelomic fluid (free of blood) . Then the oocyte together with its adherent cumulus (coronal) cells is placed in the hole. While the oocyte matures it is treated with hyaluronidase which greatly reduces the number of coronal cells and exposes the oocyte surface. After the oocyte has matured, spermatozoa are then added and co-incubated with the oocyte so as to permit fertilization.
The advantage of this approach is that the embryonic environment of the CAM is more conducive to successful fertilization and subsequent survival of the fertilized zygote than is a test tube environment. This increases the overall efficiency of the in vitro fertilization procedure.
Example 5 In the Treatment of Parkinsonism In this embodiment, the method of culturing mammalian tissue on the avian CAM, described supra, is used to condition tissue derived from autogenous adrenal medulla that is to be used for brain
transplants to treat human subjects suffering from Parkinsonism. Here too, the lack of survival of the implant at its point of insertion has emerged as the principal limitation to success of the procedure (See e.g. Ding, Y.J. et al. Chin Med J (1988) 101:631; Hansen, J.T. et al, Exp Neurol (1988) 102:65). The surgical techniques of adrenal medullary explantation and striatum implantation is known to those skilled in the art (Id.) .
Using the standard protocol of immediately transplanting adrenal tissue, the critical initial step involving fusion of capillaries at the surface of the transplant with those of this brain simply does not occur rapidly enough and extensively enough to provide for tissue survival and growth. By greatly amplifying the number of surface capillaries during the period of CAM implantation, and by the condi- tioning and proliferation of the parenchymal tissue itself, transplant survival is greatly enhanced upon subsequent reimplantation into the brain graft sites.
Example 6 In the Treatment of Parkinsonism
In this embodiment, the tissue to be implanted in the striatum of a subject afflicted with Parkinsonism is derived from human fetal tissue. More specifically, dopamine producing neurons from the ventral mesencephalic region of abortus brain tissue is implanted onto the CAM of an avian embryo. 5 to 10 days later, the conditioned fetal tissue is excised from the CAM and implanted into the striatum of a human subject suffering from Parkinsonism. Stereotaxic techniques are used to assure proper placement. These techniques are well known to those
skilled in the art. The patients are treated with a cyclosporine, azathioprine, and steroid regime to minimize the risk of graft rejection.
Example 7 In Somatic Cell Gene Therapy Using gene transfer technology known to those skilled in the art, a gene is inserted into autologous somatic cells of a patient suffering from a disease characterized by a deficiency of a naturally occurring gene product (e.g. diabetes and insulin) or a disease characterized by its ameliorative response to the introduction of a gene product (e.g. heart disease and tissue plasminogen activator) .
The choice of somatic cell type within which the treatment gene is inserted is governed by the mode of delivery desired: e.g. transduced epithelial keratinocytes are used to provide a "skin patch" from which the gene product is secreted; transduced endothelial cells are introduced into vascular grafts to provide direct secretion of a gene product into the circulatory system; and transduced parenchymal cells (such as hepatocytes) provide organ-specific introduction of a gene product.
In each case, genetically engineered (e.g. transformed or transduced) cells are first introduced onto the CAM of a developing avian embryo and cultured for 5-10 days, in the case of a chick egg, or 10-20 days in the case of an ostrich egg. During this culturing, the introduced cell population expands and forms a tissue which then becomes vascularized. This conditioned tissue is subsequently excised and homotypically reimplanted in the desired location
within the patient using the techniques described supra. Autogenic cells which have been genetically engineered may also be used in combination with the other methods of treatment described supra. For instance, adrenal medulla cells can be genetically altered to up-regulate the production of dopamine, prior to their implantation on the CAM and subsequent reimplantation in the brain of Parkinson patients.
Claims (28)
1. A method of preparing mammalian tissue for implantation in a mammalian subject which comprises: providing a developing amniote egg that has a chorioallantoic membrane (CAM) ; implanting mammalian cells or tissue on or in the CAM so as to produce a conditioned mammalian tissue comprising a population of cells; and removing the conditioned tissue from the CAM by a means for excision.
2. The method of claim 1 in which the mammal in need of implantation is human.
3. The method of claim 1 in which the amniote egg is from the class Aves.
4. The method of claim 3 in which the egg is from the genus Gallus.
5. The method of claim 3 in which the egg is from the genus Struthio.
6. The method of claim 1 in which the excision means is aspiration.
7. The method of claim 1 in which the excision means is incision.
8. The method of claim 1 in which the tissue is autogenic.
9. The method of claim 8 in which the tissue is homotypic.
10. The method of claim 8 in which the genome of a subpopulation of cells of the tissue is genetically altered.
11. The method of claim 9 in which the genome of a subpopulation of cells of the tissue is genetically altered.
12. The method of claim 11 wherein the tissue implantation is for the purpose of providing synthesis of a polypeptide in the subpopulation of cells and the genetic alteration comprises: the insertion of DNA comprising a structural sequence encoding the polypeptide; and the structural sequence being functionally linked to DNA control sequences.
13. The method of claim 12 in which the polypeptide synthesis is needed to ameliorate a genetic deficiency.
14. The method of claim 8 in which the tissue implantation is for the purpose of treating alopecia, the cells implanted on the CAM comprise stem cells derived from dermal papillae of active hair follicles of the subject, and the conditioned tissue is implanted into the dermis of the subject at a site where hair growth is desired.
15. The method of claim 8 in which the tissue implantation is for the purpose of treating Parkinsonism and the conditioned tissue is implanted into the striatum of the brain of the subject.
16. The method of claim 15 in which the tissue is derived from an adrenal medulla of said subject.
17. The method of claim 1 in which the implanted tissue is allogeneic.
18. The method of claim 17 in which the tissue implantation is for the purpose of treating Parkinsonism, and the tissue is derived from a human fetal tissue and is implanted into the striatum of the brain of the subject.
19. The method of claim 8 in which the tissue implantation is for the purpose of treating a neurologic impairment.
20. The method of claim 19 in which the tissue is derived from neurologic tissue of the subject and is implanted at the site of the impairment.
21. A method of implanting a mammalian embryo into epithelial tissue of the uterine wall of a mammalian mother comprising: providing a developing amniote egg that has a chorioallantoic membrane (CAM) ; implanting an explant of uterine epithelial tissue from the mother on or in the CAM for a given time to produce a conditioned epithelium; placing the mammalian embryo on or in the conditioned epithelium; incubating the embryo and the conditioned epithelium until the embryo implants in the conditioned epithelium, thereby forming a fertilization unit; excising the fertilization unit from the CAM; and implanting the unit back into the in vivo uterine epithelium of the mother.
22. The method of claim 21 used in conjunction with an in vitro fertilization of the ovum.
23. The method of claim 21 in which the fertilization unit is incubated for greater than 1 day but less than 20 days prior to implantation of the unit into the uterine epithelium of the mother.
24. A method of implanting a mammalian embryo into epithelial tissue of the uterine wall of a mammalian mother comprising: providing a developing amniote egg that has a chorioallantoic membrane (CAM) ; implanting a mammalian blastocyst onto or into the CAM; incubating the blastocyst for a given time; excising the blastocyst from the CAM; and implanting the blastocyst into the in vivo uterine epithelial tissue of the mother.
25. The method of claim 24 in which the blastocyst is incubated in or on the CAM for greater than 1 day but less than 20 days prior to implantation into the uterine epithelium of the mother.
26. A method of fertilizing a mammalian oocyte comprising: providing a developing amniote egg that has a chorioallantoic membrane (CAM) ; abrading a portion of the choriod epithelium of the CAM; preparing a transparent, hydrophillic plastic chip containing a hole covered with a gold screen; placing the chip on the abraded epithelium;
placing at least one mammalian oocyte into the hole; introducing spermatozoa of the same species into the hole; and co-incubating the oocyte and spermatozoa for a given period of time.
27. The method of claim 26 in which the oocyte is treated with hyaluronidase prior to the introduction of spermatozoa.
28. A composition of tissue useful for mammalian implantation comprising a mammalian tissue intended to be implanted into a mammalian host, and growth factors derived from avian CAM tissue; the mammalian tissue having been first implanted in or on the CAM of a developing amniote egg for a given time such that the mammalian tissue has become substantially amplified, vascularized and conditioned as a result of the implantation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51329090A | 1990-04-17 | 1990-04-17 | |
US513290 | 1990-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU7746091A true AU7746091A (en) | 1991-11-11 |
Family
ID=24042643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU77460/91A Abandoned AU7746091A (en) | 1990-04-17 | 1991-04-17 | Methods of tissue implantation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0528842A4 (en) |
JP (1) | JPH05509292A (en) |
AU (1) | AU7746091A (en) |
CA (1) | CA2080464A1 (en) |
WO (1) | WO1991016419A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10005329A1 (en) * | 2000-02-08 | 2001-09-20 | Albert Scheller | Stimulating growth of hair, e.g. on the head, eyebrows or eyelashes, by subcutaneous application of a preparation containing stem cells and/or preformed hair cells |
AU2001247732A1 (en) * | 2000-03-24 | 2001-10-08 | Geron Corporation | A strategy for maintaining pregnancy |
CN100362972C (en) * | 2004-12-24 | 2008-01-23 | 李宇 | Artificial hair mammilla substition structure and its manufacturing method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
AU6131086A (en) * | 1985-07-05 | 1987-01-30 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
GB8604360D0 (en) * | 1986-02-21 | 1986-03-26 | Univ Dundee | Stimulation of hair growth |
-
1991
- 1991-04-17 WO PCT/US1991/002629 patent/WO1991016419A1/en not_active Application Discontinuation
- 1991-04-17 JP JP3508056A patent/JPH05509292A/en active Pending
- 1991-04-17 AU AU77460/91A patent/AU7746091A/en not_active Abandoned
- 1991-04-17 EP EP19910908414 patent/EP0528842A4/en not_active Withdrawn
- 1991-04-17 CA CA002080464A patent/CA2080464A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2080464A1 (en) | 1991-10-18 |
EP0528842A1 (en) | 1993-03-03 |
WO1991016419A1 (en) | 1991-10-31 |
JPH05509292A (en) | 1993-12-22 |
EP0528842A4 (en) | 1993-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Borges et al. | Chorioallantoic membrane angiogenesis model for tissue engineering: a new twist on a classic model | |
Billingham et al. | Studies on the conservation of epidermal specificities of skin and certain mucosas in adult mammals | |
CN101757691B (en) | Preparation method of tissue engineering cornea | |
MORIYAMA et al. | Progesterone facilitates implantation of xenogenic cultured cells in hamster uterus | |
CN100503814C (en) | Methods of preparing a transplantable product for treatment of skin defects | |
Hsu | Differentiation in vitro of mouse embryos to the stage of early somite | |
JPWO2005087286A1 (en) | Biological tissue sheet, method for producing the same, and transplantation method using the same | |
WO2008083223A1 (en) | Methods for culturing dermal cells for treatment of skin injuries such as burns | |
CN101102800A (en) | Sheet-shaped composition utilizing amnion and method of preparing the same | |
EP1702632B1 (en) | Hair growth method | |
US20200078492A1 (en) | Process for obtaining a functional dermal substitute of decellurized amniotic membrane from the placenta combination with keratinocytes and its use as an agent for tissue regeneration of the skin | |
CN104087551A (en) | Novel method for in-vitro separated culture of human epidermal cells | |
Boyce | Methods for the Serum-Free Culture of Keratinocytes and Transplantation of Collagen—GAG-Based Skin Substitutes | |
Hsu | Embryo growth and differentiation factors in embryonic sera of mammals | |
US20030202965A1 (en) | Methods and compositions for the preparation of cell transplants | |
KR20120127468A (en) | Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use | |
US6585969B1 (en) | Non-viable keratinocyte cell composition or lysate for promoting wound healing | |
AU7746091A (en) | Methods of tissue implantation | |
TWI389696B (en) | Artificial kidney precursor and process for producing the same | |
JP2001518445A (en) | Gene therapy vehicle consisting of dermal sheath tissue | |
JP5164439B2 (en) | Hair papilla cell culture method | |
CN107338216A (en) | Artificial epidermal graft, its preparation method and application | |
CN110199985A (en) | A kind of preparation method of neuron frozen stock solution | |
Yanoff | Biology in vitro of corneal epithelium and endothelium | |
CN114134107B (en) | Artificial ovary with mesenchymal stem cells participating, and preparation method and application thereof |